Insights on the Real World Evidence Solutions Global Market to 2030 - Featuring Flatiron Health, IBM and ICON Among Others - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Real World Evidence Solutions Market Share, Size, Trends, Industry Analysis Report, By Component; By Therapeutic Areas : By End-User; By Region; Segment Forecast, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.

The global real world evidence solutions market size is expected to reach USD 3.96 billion by 2030, according to a new study. The report gives a detailed insight into current market dynamics and provides analysis on future market growth.

With regulatory authorities encouraging RWE solutions, the global evidence results industry will likely grow significantly throughout the forecast period. Regulators use RWE to observe the security of marketed pharmaceuticals by combining traditional pharmacovigilance approaches with modern digital tools.

Legislators also recognize the significance of RWE. It encourages patient-centered medication development and has improved clinical trial design and review. Regulators also indicate a desire for RWE to play a prominent role in their operations. However, industry growth is likely to be spurred by drug development delays, which would increase development costs.

Further, RWE is used by regulatory agencies to monitor the safety of packaged goods using traditional pharmacovigilance tools and newer digital tools such as the FDA Sentinel Initiative, a comment active safety surveillance system. RWE is presently being utilized in pre-approved efficacy decisions. It can be used more extensively in oncology, uncommon diseases, and pediatric ailments where randomized controlled clinical trials are impractical or unethical. Simultaneously, legislators realize the importance of RWE.

Based on the end-user, the pharmaceutical and medical devices segment accounted for the leading share in the industry in 2021. This segment is also expected to increase at the fastest rate over the projected period. This end-user segment's substantial share and rapid expansion can be related to the growing use of RWE studies in medication approvals and the increasing requirement to evaluate drug performance in world situations.

Market Dynamics

Drivers and Opportunities

• Support from regulatory bodies for the use of RWE solutions
• Rising focus on end-to-end RWE services

Restraints and Challenges

• Reluctance to rely on real-world studies

The publisher has segmented the real world evidence solutions market report based on component, end-user, therapeutic areas, and region:

Real World Evidence Solutions, Component Outlook (Revenue - USD Billion, 2018 - 2030)

• DataSets
• Disparate Datasets
• HER/Clinical setting data
• Claims and billing data
• Pharmacy data
• Patient powered data
• Other Datasets
• Integrated datasets
• Consulting and Analytics

Real World Evidence Solutions, Therapeutic Areas Outlook (Revenue - USD Billion, 2018 - 2030)

• Oncology
• Cardiovascular
• Neurology
• Immunology
• Others

Real World Evidence Solutions, End-User Outlook (Revenue - USD Billion, 2018 - 2030)

• Pharmaceutical and Medical Devices Companies
• Healthcare Providers
• Healthcare Payers
• Other End Users

Real World Evidence Solutions, Regional Outlook (Revenue - USD Billion, 2018 - 2030)

• North America
• U.S.
• Canada
• Europe
• France
• Germany
• UK
• Italy
• Netherlands
• Spain
• Austria
• Asia Pacific
• China
• India
• Japan
• Malaysia
• South Korea
• Indonesia
• Latin America
• Mexico
• Brazil
• Argentina
• Middle East & Africa
• UAE
• Saudi Arabia
• Israel
• South Africa

Companies Mentioned

• CLARIVATE PLC
• Clinigen Group plc
• Cognizant Technology Solutions Corporation
• Flatiron Health Inc.
• IBM Corporation
• ICON plc
• IQVIA Holdings Inc.
• Medpace Holdings Inc.
• Oracle Corporation
• PAREXEL International Corporation
• PerkinElmer Inc.
• PPD Inc.
• SAS Institute Inc.
• Symphony Innovation LLC
• SYNEOS HEALTH Inc.
• UnitedHealth Group Incorporated

For more information about this report visit https://www.researchandmarkets.com/r/wbieog